Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $34.79 USD
Change Today 0.00 / 0.00%
Volume 0.0
VASC On Other Exchanges
As of 8:10 PM 07/1/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

6464 Sycamore Court North

Minneapolis, MN 55369

United States

Phone: 763-656-4300

Fax: 877-656-4251

Vascular Solutions, Inc. operates as a vertically-integrated medical device company. Products and Services The company’s products and services are divided into three categories: Catheter products, Hemostat products, and Vein products and services. Catheter products Catheter products consist principally of catheters used in minimally invasive medical procedures for the diagnosis or treatment of vascular conditions, such as the GuideLiner catheter used to access discrete regions of the coronary anatomy and the Pronto extraction catheters used in treating acute myocardial infarction. This category also includes products used in connection with gaining percutaneous access to the vasculature to perform minimally invasive procedures, such as micro-introducer kits. The GuideLiner catheter is a unique coaxial ‘mother and child’ guide extension with rapid exchange convenience that enables deep seating, guide back-up support, and selective intubation in coronary interventions. In 2011, the company launched the second generation of its GuideLiner catheter with increased flexibility, a smaller size version, and a longer extension. In August 2013, the company launched the third generation version, GuideLiner V3, which features a polymer ‘half-pipe’ collar to enhance stent and wire deployment. The company’s Pronto catheters consist of a catheter with a proprietary distal tip and large extraction lumen that can be delivered into arteries to mechanically remove blood clots using simple vacuum suction. In 2005, the company launched the third generation design of the Pronto, named the Pronto V3. In addition to the Pronto V3 and V4, the company has developed and launched five additional versions of extraction catheters - the Pronto-Short, Pronto 035, Pronto LP, QXT and XL. The Pronto-Short is a shorter and larger version, designed for use in clotted dialysis grafts that was launched in 2005. The Pronto 035 is a much larger version, designed for use in large vessels that was launched in 2007. The Pronto LP is a low profile version, designed for use in smaller vessels that was launched in 2008. The QXT is a low-cost version, designed to be sold in certain international markets that was launched in 2008. The XL extraction catheter is a larger version with either a straight or pigtail tip, designed for use in larger vessels that was launched in 2012. In 2003, the company launched various access kit products used to gain percutaneous access to the vasculature for performing arterial and venous catheterization procedures. These products include a full line of micro-introducer kits and various specialty guidewires. In 2004, the company received regulatory clearance in the United States for the Langston dual lumen pigtail catheter. The Langston catheter is used for the measurement of intravascular pressure gradients, primarily measured to diagnose aortic valve stenosis. In 2011, the company launched the second version of its Langston catheter with improved pressure measurement and reduced kinking. In 2010, the company acquired the SmartNeedle and pdACCESS Doppler guided needle products from Escalon Vascular Access, Inc. The SmartNeedle and pdACCESS products consist of a hand-held monitor and one-time use needles designed to provide auditory ultrasound guided access to arteries and veins during catheterization procedures. In 2012, the company acquired the Venture catheter from St. Jude Medical. After integrating manufacturing operations into its own facilities, the company re-launched Venture in the U.S. in April 2013 and in international markets in August 2013. There are three versions of the Venture catheter: rapid exchange (Rx), over-the-wire (OTW), and coronary sinus (CS). The Venture catheters are indicated for directing, steering, controlling, and supporting a guidewire to access discrete regions of the coronary and peripheral vasculature. During 2007, the company entered into an agreement with Zerusa Limited (Zerusa) to act as the exclusive U.S. distributor of Zerusa’s Guardian hemostatic valve. The Guardian hemostatic valve is a valve used in catheterization procedures to allow the placement of multiple d


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VASC:US $34.79 USD 0.00

VASC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AtriCure Inc $24.02 USD 0.00
Cardiovascular Systems Inc $25.70 USD 0.00
CryoLife Inc $11.31 USD 0.00
Endologix Inc $14.83 USD 0.00
STAAR Surgical Co $9.43 USD 0.00
View Industry Companies

Industry Analysis


Industry Average

Valuation VASC Industry Range
Price/Earnings 50.9x
Price/Sales 4.5x
Price/Book 5.2x
Price/Cash Flow 43.5x
TEV/Sales 4.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VASCULAR SOLUTIONS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at